Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BMY, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-05-13 | Mezigdomide | NDA | 66% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nivolumab FDA approved Dec 2014 · Opdivo |
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… | Phase 2/3 · NCT07221149 | Recruiting |
| Mavacamten FDA approved Apr 2022 · Camzyos |
Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 · NCT07940777 | Not yet recruiting |
| Apixaban FDA approved Dec 2012 · Eliquis |
Atrial Fibrillation | Phase 3 · NCT05757869 | Active not recruiting |
| Belatacept FDA approved Jun 2011 · Nulojix |
Highly Sensitized Prospective Kidney Transplant Recipients | Phase 1/2 · NCT05017545 | Active not recruiting |
| Ipilimumab FDA approved Mar 2011 · Yervoy |
Meningiomas | Phase 2 · NCT02648997 | Active not recruiting |
| Fedratinib FDA approved Aug 2019 · Inrebic |
Primary Myelofibrosis | Phase 1/2 · NCT04446650 | Completed |
| Luspatercept FDA approved Nov 2019 · Reblozyl |
Myelodysplastic Neoplasms | N/A · NCT07752121 | Recruiting |
| Xanomeline | Schizophrenia | Phase 4 · NCT07221877 | Recruiting |
| FOLFOX | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… | Phase 2/3 · NCT07221149 | Recruiting |
| Izalontamab Brengitecan | Non-Small Cell Lung Cancer | Phase 3 · NCT07680790 | Recruiting |
| Milvexian | Atrial Fibrillation | Phase 3 · NCT05757869 | Active not recruiting |
| Nab-paclitaxel | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | Phase 2/3 · NCT07063745 | Recruiting |
| KarX-EC | Schizophrenia | Phase 3 · NCT07424404 | Recruiting |
| Osimertinib | Non-Small Cell Lung Cancer | Phase 3 · NCT07680790 | Recruiting |
| Pumitamig | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… | Phase 2/3 · NCT07221149 | Recruiting |
| Relatlimab | Non-small Cell Lung Cancer | Phase 3 · NCT06561386 | Recruiting |
Also used in these trials (approved or third-party drugs, not BMY's own candidates): Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Amivantamab, Atezolizumab, Carboplatin, Bevacizumab, Oxaliplatin, Obinutuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BMY holds $13B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 173,661,963 | 8.50% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 153,108,018 | 7.49% | 2026-03-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 102,521,748 | 5.02% | 2026-06-30 |
| Charles Schwab Investment Management, In | Institution (13F) | 72,453,484 | 3.54% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 60,215,293 | 2.95% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 50,641,973 | 2.48% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 47,061,976 | 2.30% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 40,278,707 | 1.97% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 28,379,740 | 1.39% | 2026-09-30 |
| David V Elkins EVP, Chief Financial Officer · +96,067 options |
Insider | 159,542 | 0.01% | 2026-04-01 |
| Christopher S. Boerner Chief Executive Officer, Director · +270,924 options |
Insider | 148,536 | 0.01% | 2026-11-01 |
| Gregory Scott Meyers EVP, Chief Digital & Tech Off. · +74,881 options |
Insider | 33,977 | 0.00% | 2026-11-01 |
Share count 2,044,085,831 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-05 filed 2026-11-06 |
Haller Julia A |
Sale (S) | 3,800 | $63.31 | 30,279 |
| 2026-11-03 filed 2026-11-04 |
Lenkowsky Adam |
Option exercise (M) | 7,522 | – | 27,228 |
| 2026-11-03 filed 2026-11-04 |
Lenkowsky Adam |
Tax withholding (F) | 3,848 | $61.71 | 23,380 |
| 2026-11-03 filed 2026-11-04 |
Lenkowsky Adam |
Option exercise (M) | 7,522 | – | – |
| 2026-11-01 filed 2026-11-03 |
BOERNER CHRISTOPHER S. |
Option exercise (M) | 2,964 | – | 24,415 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →